| 英文别名 |
Volitinib;AZD-6094;HMPL-504;1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine;Savolitinib;AZD6094;HMPL504;2A2DA6857R;(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine;3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine;Savolitinib [INN];Volitinib(Savolitinib);Savolitinib (USAN/INN);Savolitinib [USAN:INN];GTPL9918;HMPL 504;AZD 6094;BDBM50023342;NSC782121;Volitinib;Savolitinib;AZD-6094;NS00073442;HY-15959;UNII-2A2DA6857R;EN300-7482485;Savolitinib(AZD6094, HMPL-504);C17H15N9;SCHEMBL12489208;DTXSID801111016;Volitinib dihydrochloride;Savolitinib (JAN/USAN/INN);BV160378;AZD6094 dihydrochloride;NSC800966;NSC-800966;DB12048;(3E)-5-Chloro-3-[(5-{3-[(4-methyl-1,4-diazepan-1-yl)carbonyl]phenyl}-2-furyl)methylene]-1,3-dihydro-2H-indol-2-one hydrochloride;HM 5016504;savolitinibum;Z3041529961;BRD-K98028353-001-01-0;CHEBI:231369;HMPL-504 dihydrochloride;Savolitinib dihydrochloride;Q27254463;SAVOLITINIB [WHO-DD];(S)-1-(1-(imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine dihydrochloride;4-{1-[(1S)-1-{imidazo[1,2-a]pyridin-6-yl}ethyl]-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl}-1-methyl-1H-pyrazole;D11139;s7674;AC-35267;EX-A845;1-((S)-1-(IMIDAZO(1,2-A)PYRIDIN-6-YL)ETHYL)-6-(1-METHYL-1H-PYRAZOL-4-YL)-1H-(1,2,3)-TRIAZOLO(4,5-B)PYRAZINE;MFCD28359096;Orpathys;1H-1,2,3-Triazolo(4,5-b)pyrazine, 1-((1S)-1-imidazo(1,2-a)pyridin-6-ylethyl)-6-(1-methyl-1H-pyrazol-4-yl)-;1313725-88-0;NCGC00475727-01;AS-35250;NSC-782121;HM-5016504;CCG-267976;J-690125;AZD6094, HMPL-504;compound 28 [PMID: 25148209];Savolitinib;Volitinib;HMPL-504;AZD-6094;1-[(1S)-1-(imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine;Volitinib; 1-[(1S)-1-Imidazo[1,2-a]pyridin-6-ylethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-1,2,3-triazolo[4,5-b]pyrazine; AZD 6094; HM 5016504; HMPL 504;CHEMBL3334567;SAVOLITINIB [USAN];AKOS030526403 |